Agency Information Collection Activities; Submission for Office of Management and Budget Review; Administrative Procedures for the Clinical Laboratory Improvement Amendments of 1998 Categorization; Correction, 50112 [E7-17153]
Download as PDF
<![CDATA[
50112
Federal Register / Vol. 72, No. 168 / Thursday, August 30, 2007 / Notices
and small business knowledge in
general.
FOR FURTHER INFORMATION CONTACT:
Aaron Collmann, Room 6029, GSA
Building, 1800 F Street, NW.,
Washington, DC 20405 (202) 501–1021
or email at sbac@gsa.gov.
SUPPLEMENTARY INFORMATION: This
notice is published in accordance with
the provisions of the Federal Advisory
Committee Act (FACA) (Pub. L. 92–
463).
Dated: August 27, 2007
Michael J. Rigas
Deputy Associate Administrator,Office of
Small Business Utilization,General Services
Administration.
[FR Doc. 07–4282 Filed 8–28–07; 12:35 pm]
BILLING CODE 6820–34–S
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Food and Drug Administration
[Docket No. 2007N–0041]
Agency Information Collection
Activities; Submission for Office of
Management and Budget Review;
Administrative Procedures for the
Clinical Laboratory Improvement
Amendments of 1998 Categorization;
Correction
AGENCY:
Food and Drug Administration,
HHS.
ACTION:
Notice; correction.
SUMMARY: The Food and Drug
Administration (FDA) is correcting a
notice that appeared in the Federal
Register of May 16, 2007 (72 FR 27573).
The document announced that a
proposed collection of information had
been submitted to the Office of
Management and Budget (OMB) for
review and clearance under the
Paperwork Reduction Act of 1995. The
document was published with an error.
This document corrects that error.
FOR FURTHER INFORMATION CONTACT:
Denver Presley, Jr., Office of the Chief
Information Officer (HFA–250), Food
and Drug Administration, 5600 Fishers
Lane, Rockville, MD 20857, 301–827–
1472.
In FR Doc.
E7–9435, appearing on page 27573 in
the Federal Register of Wednesday, May
16, 2007, the following correction is
made:
1. On page 27574, in the third
column, in the third full paragraph, the
sentence ‘‘The likely respondents for
this collection are Investigational New
Drug Application Sponsors.’’ is
rfrederick on PROD1PC67 with NOTICES
SUPPLEMENTARY INFORMATION:
VerDate Aug<31>2005
14:38 Aug 29, 2007
Jkt 211001
corrected to read ‘‘The likely
respondents for this collection of
information are manufacturers of
medical devices.’’
Dated: August 23, 2007.
Jeffrey Shuren,
Assistant Commissioner for Policy.
[FR Doc. E7–17153 Filed 8–29–07; 8:45 am]
BILLING CODE 4160–01–S
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Food and Drug Administration
Office of the Commissioner; Statement
of Organizations, Functions, and
Delegations of Authority
Part D, Chapter D–B, (Food and Drug
Administration), of the Statement of
Organization, Functions, and
Delegations of Authority for the
Department of Health and Human
Services (35 FR 3685, February 25,
1970, and 60 FR 56605, November 9,
1995, 64 FR 36361, July 6, 1999, and in
pertinent part at 57 FR 54239) is being
amended to reflect the restructuring of
the Office of the Commissioner (OC),
Food and Drug Administration (FDA).
This reorganization includes the
establishment of four Deputy-level
offices within the Office of the
Commissioner, the changes are as
follows:
I. Under Part D, Food and Drug
Administration, delete the Office of the
Commissioner (DA) in its entirety and
replace with the following:
DA.10 Organization. The Food and
Drug Administration (FDA) is headed by
the Commissioner, Food and Drug and
includes the following organizational
units:
Office of the Commissioner (DA),
Office of the Chief Counsel (DAA),
Office of the Chief of Staff (DAB), Office
of International and Special Programs
(DAL), Office of Operations (DAM),
Office of Policy, Planning and
Preparedness (DAH), Office of Scientific
and Medical Programs (DAE).
DA.20 Functions
A. Office of the Commissioner D(A)—
The Office of the Commissioner (OC)
includes the Commissioner and Deputy
Commissioner who are responsible for
the efficient and effective
implementation of FDA mission.
B. Office of the Chief Counsel
(DAA)—The Office of the Chief Counsel
(OCC) is also known as the Food and
Drug Division, Office of the General
Counsel, Department of Health and
Human Services), while
administratively within the Office of the
Commissioner, is part of the Office of
PO 00000
Frm 00017
Fmt 4703
Sfmt 4703
the General Counsel of the Department
of Health and Human Services.
1. Is subject to the professional
supervision and control of the General
Counsel, Department of Health and
Human Services (HHS), and represents
FDA in court proceedings and
administrative hearings with respect to
programs administered by FDA.
2. Provides legal advice and policy
guidance for programs administered by
FDA.
3. Acts as liaison to the Department of
Justice and other Federal agencies for
programs administered by FDA.
4. Drafts or reviews all proposed and
final regulations and Federal Register
notices prepared by FDA.
5. Performs legal research and gives
legal opinions on regulatory issues,
actions, and petitions submitted to FDA.
6. Reviews proposed legislation
affecting FDA that originates in HHS or
on which Congress requests the views of
the Department.
7. Provides legal advice and
assistance to the Office of the Secretary
on matters within the expertise of the
Chief Counsel.
C. Office of the Chief of Staff (DAB)—
The Office of the Chief of Staff (OCOS):
1. Advises and provides integrated
policy analysis and strategic
consultation to the Commissioner,
Deputy Commissioners, Associate
Commissioners, Center Directors and
other FDA officials on activities and
issues that affect significant agency
programs, projects and initiatives. Often
this function involves the most difficult
problems, crisis situations and
extremely complex issues of FDA.
2. Provides leadership, coordination
and management of the Commissioner’s
priority policies and issues across the
Office of the Commissioner and FDAwide. Identifies, triages, supervises and
tracks related actions from start to finish
in conjunction with senior leadership
across FDA.
3. Provides ddidrect support to the
Commissioner of Food and Drugs and
serves as major point of contact between
the FDA Centers and Offices and the
Commissioner.
4. Serves as the principal liaison to
HHS and coordinates and manages
activities between FDA and HHS. Works
with the FDA Centers and Offices to
ensure assignments or commitments
made related to these activities are
carried out.
5. Serves as one of the
Commissioner’s primary strategic
liaisons with staff, partners, and the
community at large.
6. Manages budget and resources and
provides operation oversight for the
FDA’s Office of Legislation, Office of the
E:\FR\FM\30AUN1.SGM
30AUN1
]]>Agencies
[Federal Register Volume 72, Number 168 (Thursday, August 30, 2007)]
[Notices]
[Page 50112]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: E7-17153]
=======================================================================
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Food and Drug Administration
[Docket No. 2007N-0041]
Agency Information Collection Activities; Submission for Office
of Management and Budget Review; Administrative Procedures for the
Clinical Laboratory Improvement Amendments of 1998 Categorization;
Correction
AGENCY: Food and Drug Administration, HHS.
ACTION: Notice; correction.
-----------------------------------------------------------------------
SUMMARY: The Food and Drug Administration (FDA) is correcting a notice
that appeared in the Federal Register of May 16, 2007 (72 FR 27573).
The document announced that a proposed collection of information had
been submitted to the Office of Management and Budget (OMB) for review
and clearance under the Paperwork Reduction Act of 1995. The document
was published with an error. This document corrects that error.
FOR FURTHER INFORMATION CONTACT: Denver Presley, Jr., Office of the
Chief Information Officer (HFA-250), Food and Drug Administration, 5600
Fishers Lane, Rockville, MD 20857, 301-827-1472.
SUPPLEMENTARY INFORMATION: In FR Doc. E7-9435, appearing on page 27573
in the Federal Register of Wednesday, May 16, 2007, the following
correction is made:
1. On page 27574, in the third column, in the third full paragraph,
the sentence ``The likely respondents for this collection are
Investigational New Drug Application Sponsors.'' is corrected to read
``The likely respondents for this collection of information are
manufacturers of medical devices.''
Dated: August 23, 2007.
Jeffrey Shuren,
Assistant Commissioner for Policy.
[FR Doc. E7-17153 Filed 8-29-07; 8:45 am]
BILLING CODE 4160-01-S
